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Abstract
Purinergic receptors are a class of receptors distributed into two groups, P1 and
P2. P1 receptors are activated by nucleosides, like adenosine, while nucleotides
active P2 receptors. In turn, P2 receptors comprise two families, metabotropic P2Y
and ionotropic P2X. P2Y receptors consist in eight members, namely, P2Y1, P2Y2,
P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and P2Y14, described in mammals, while P2X
includes seven members, numbered P2X1 to P2X7. These receptors have been
described as expressed in practically all cells studied to date. In this context, P2
receptors are suggested as participating in certain diseases. The general approach
applied in the discovery of new drugs is expensive and lengthy. Alternatively, in the
last 20 years, molecular modeling has emerged as an exciting tool for the design of
new drugs, in less time and at low costs. These tools allow for in silico testing of
thousands of molecules against a target protein, as well as toxicity, absorption,
distribution, metabolism, and constant affinity predictions of a given interaction.
Thus, molecular modeling algorithms emerge as an increasingly important tool for
the design of drugs targeting purinergic receptors as therapeutic targets of many
diseases, including cancer, pain, inflammation, cardiovascular, and endocrine
conditions.
Keywords: molecular modeling, molecular dynamics, virtual screening,
homology modeling, drug discovery, P2X receptors, P2Y receptors
1. Introduction
Purinergic receptors are a class of transmembrane proteins activated by
extracellular nucleotides and nucleosides. They consist in the P1 receptor (mainly
activated by adenosine) and P2 receptors distributed into two families, P2Y
(G protein-coupled receptors) and P2X (ionotropic receptor).
P2Y receptors comprise eight members in mammals (P2Y1, P2Y2, P2Y4, P2Y6,
P2Y11, P2Y12, P2Y13, P2Y14) and are activated mainly by adenosine diphosphate
and uracil nucleotides, such as UTP and UDP. Regarding distribution, P2Y receptors
are widely distributed throughout the organism. The structure of P2Y receptors
comprises seven transmembrane segments with an extracellular amino terminal, an
intracellular carboxyl-terminal, and three segments connecting the transmembrane
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domains, and two subtypes have been resolved by X-ray crystallography, P2Y1 and
P2Y12 [1–3].
The first resolved P2Y structure was P2Y12 in 2014, in two papers published by
Zhao group describing the crystal structure (Figure 1) of the receptor bound to an
antithrombotic drug and two agonists (2MeSADP and 2MeSATP) [1, 3]. As this
receptor is related to thrombosis, with at least three drugs available in the market,
this finding was relevant to address the development of new antithrombotic drugs.
Surprisingly, the authors also reported a different behavior of the receptor linked to
nucleotide and non-nucleotide ligands, presenting different binding pockets that
share only a small portion of the site.
Another subtype that has been resolved by X-ray crystallography is P2Y1 that
plays a similar role in thrombosis, facilitating platelet aggregation, and that could be
a new candidate for the discovery of antithrombotic treatments. In this case, the
resolution was even higher, at 2.2 Å, than P2Y12. The authors described two distinct
binding pockets, one allosteric and another orthosteric. The allosteric site is located
close to the lipid bilayer, while the orthosteric site is formed by an extracellular
loop-2, VI and VII helices, and a portion of the amino-termini domain. It is
important to note that the binding modes are entirely different from that reported
for P2Y12.
Regarding P2X receptors, these are nonselective cation channels gated by extra-
cellular ATP, also expressed in various systems throughout the organism [4–6]. To
date, seven different P2X subtypes (P2X1–P2X7) have been found, assembled as
homo- or heterotrimers with two transmembrane segments, an extracellular ligand
binding loop and both intracellular amino and carboxy termini that modulate chan-
nel gating [7, 8]. In general, the P2X receptors when activated open a channel
permeating mono and divalent cations except for the P2X5 that permeates anions
as. Another receptor that has a different behavior is the P2X7 that opens a channel
activated by low concentrations of ATP, but under high concentration stimulation
Figure 1.
Three-dimensional structure of P2Y12 bound to 2MeSADP. (A) Crystal structure of P2Y12 (PDB code 4PXZ)
with the transmembrane regions depicted in pink. The receptor structure is represented as a cartoon comprising
different colors (gray, light blue, and green). 2MeSADP molecules are shown as a stick representation.
(B) P2Y12 crystal structure without any ligand (PDB code 4PXZ). In (B), each helix is shown as
a different color.
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(>100 μM), it opens a pore, allowing the passage of molecules up to 900 Da,
including fluorescent molecules [9–11]. With the recent crystal structure determi-
nation of some P2X receptors, some of the questions and hypothesis gathered in
previous studies were confirmed, and it was also possible to postulate a reasonable
mechanism for channel activation [8]. However, the molecular machinery involved
in the high-conductance pore formation remains uncertain and under discussion.
A significant advance in the understanding of P2X receptors was the determina-
tion of the crystal structures of zebrafish P2X4 (zfP2X4) in both the apo- (closed-
channel state) and ATP-bound (open-channel state) forms (Figure 2) [12]. Before
this, assumptions concerning the receptor structures were carried out through
bioinformatics and molecular and biochemical studies, since overexpression,
reconstitution, and the overall structure determination of membrane proteins are
challenging [13]. In addition, no sequence homology exists between P2X and other
ion channels [14]. Therefore, the crystallographic structures of zfP2X4 demon-
strated the particular three-dimensional organization of the P2X family and the
folding of each subunit, marking a new era for P2X studies.
The architecture of P2X receptors is compared to a dolphin [8] (Figure 1),
where the highly conserved residues, found in a rigid β-sheet structure, form a
sizeable glycosylated ectodomain denoted as the dolphin body. Four other flexible
domains make up the head, dorsal fin, and left and right flippers. The TM1 and TM2
Figure 2.
Three-dimensional structures of the closed and open (ATP-bound) P2X4 states. (A) Crystal structure of the
zfP2X4 in a closed state (PDB code 4DW0) with the transmembrane regions depicted in blue and red. The
three subunits are represented as a cartoon and in different colors (gray, light blue, and green). (B) Crystal
structure of the zfP2X4 bound to ATP (PDB code 4DW1). ATP molecules are displayed as a van der Waals
(vdw) representation. One of the subunits is colored according to the dolphin-like model. (C) The same
structure as in (A), viewed from the top along the axis of the central channel. (D) The same structure as in (B),
seen from the top along the axis of the central channel.
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transmembrane domains (dolphin tail) are organized into alpha helices, and the
ion-conducting channel is formed by the association of three of the TM2 alpha
helices. It was also possible through the zfP2X4 crystal structures to confirm the
ATP-binding site region [12]. The residues are located within a cavity surrounded
by the head, left flipper, and dorsal fin [8]. Besides, two possible ion pathways were
recognized. Ions theoretically either pass through the channel vertically, through
three related vestibules positioned along the central axis of the receptors, or laterally
through three fenestrations positioned above the gate region, located approximately
halfway down the length of the TM2 helix [8].
Over the years, crystal structure determination and in silico modeling allowed
for inferences regarding gating action. Gating may begin with ATP binding that
incites conformation changes all around the receptor and the contraction of regions
surrounding the ATP-binding site. Subunits bend outside and rotate, flexing the
lower regions of the receptor and the extension of the lateral fenestrations. Since the
lower areas of the receptor are connected to the transmembrane domain, their
movement displaces the outer ends of the TM helices, followed by pore
opening [15].
Recently, other P2X crystal structures have been determined, such as the Gulf
Coast tick P2X (gcP2X) receptor [7], the human P2X3 (hP2X3) receptor [16, 17],
the panda P2X7 (pdP2X7) receptor [18], and the chicken P2X7 (ckP2X7) receptor
[7]. Surprisingly, it has been demonstrated that some antagonists thought to be
competitive antagonists were, in fact, allosteric antagonists. These structures led to
an understanding concerning channel activation, desensitization, and the recogni-
tion of P2X family agonists and antagonists. On the one hand, the elucidation of the
various P2X structures opens the possibility of structural comparisons between
subtypes. For instance, the ckP2X7 conformation was noted as presenting an
extended, incompletely activated conformation of the channel and a different ATP
recognition mechanism compared to other P2X crystal structures [7]. On the other
hand, the availability of crystal structures in both open- and closed-channel states
also increases the use of computational methods to predict P2X receptor structures
from sequences and aid in drug design studies targeting the P2X family.
2. In silico approaches applied to drug discovery
The classical pharmacology approach to study protein and ligand interactions
searching for new drugs based on high-throughput screening with thousands of
molecules takes up significant amounts of time and financial resources. The
computational approach, on the other hand, allows for substantial overall cost
reductions.
In silico methods comprising pharmacophore modeling, homology models,
quantitative structure-activity relationships, molecular docking, or databases are
mostly used alongside other experimental techniques, such as in vitro methodolo-
gies, creating models to test, discover, and optimize molecules to attribute a phar-
macological target. The in silico approaches to drug discovery or computational
pharmacology and therapeutics comprise biomedical data for simulations and
predictions, suggesting hypotheses and aiding in creating shortcuts between the
idea and the designed drug, whereas all new drug design process takes about
15 years [19].
In silico approaches alter the way the pharmacology industry discovers and
optimizes drugs, using human genome information. The genomic sequence emerges
with confidence in biological and chemical sciences [20, 21]. The various gene-
sequenced species to date, including humans, have contributed to increasing all
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databases and databanks worldwide. Besides, the new biochemistry challenge is to
apply this information to solve the 3D structure of macromolecules, mainly proteins
(i.e., enzymes, receptors). As these structures order the major functionality of the
human body, reading, solving, and interpreting this structural information may be
the future of medicine. Elucidating protein structures opens up possibilities for drug
research using the solved 3D structures as molecular targets [22]. However,
although available gene and protein information exist, a knowledge gap is also
observed [23]. In this context, structure-based methods are frequently used to
predict or optimize new drugs, enabling both improvements and predictions
concerning pharmacodynamic (bioactivity and toxicity) and pharmacokinetic
(absorption, distribution, metabolism, and excretion) properties [24].
However, each approach was developed for a specific proposal, and none was
capable of solving all issues. In this sense, over time many researchers have noted
that mixed strategies can be used as complementary, filling the gaps present in each
method. This point of view emerges to aid in the study of human P2 receptors, as no
experimental 3D structure is available. In this sense, comparative modeling based
on homologous template proteins associated with molecular docking and a virtual
screening (VS) approach is a standard protocol for computer-aided drug design.
The following section details some procedures applied to computational structure-
activity relationship studies.
2.1 Comparative modeling
The experimental determination of a protein structure is frequently delayed by
difficulties in the cloning, expression, and purification of the target protein. Addi-
tionally, technical and methodological problems concerning crystallization can also
occur, which may nullify the effort to obtain a crystal structure. Therefore, methods
that deal with structure prediction are highly sought out. One of these methods is
termed comparative modeling, also known as homology modeling. This method is
based on the concept that two proteins from the same family, which share similar-
ities in their amino acid sequence, will display similar three-dimensional structures,
as the degree of conservation of three-dimensional structure elements in a protein
family is higher than sequence conservation.
The precision of comparative modeling relies on the sequence alignment
between what is called the template (related homologous protein) and the target
sequence (protein to be constructed) [25]. Usually, the sequence identity must be
higher than 70% to ensure a successful prediction, as sequence identities lower than
30% may produce models presenting inaccurate structural predictions. Membrane
proteins, especially transmembrane domains, can be constructed into acceptable
models with sequence identities equal or higher than 30%, although the alignments
in soluble regions may be less accurate [26]. In addition to sequence identity,
inherited structural deficiencies, such as crystal packing and the presence of deter-
gents for solubilization from the template structure, may also contribute to an
unreliable predicted model. Popular comparative modeling programs include
MODELER, SWISS-MODEL, and ROSETTA [27–29].
Predicted receptor structures for P2X1, P2X2, P2X3, P2X4, and P2X7 have been
constructed in several studies (see more details in the review by Grimes and Young)
[30]. These structural studies provided evidence to the identification of the critical
amino acid residues and regions of the P2X receptor function have been previously
investigated only by experimental assessments. In addition, comparative modeling
has led to interesting developments regarding modified P2X receptors, by point
mutations in important residues. Mutations in crucial residues can introduce dif-
ferent mobility concerning channel opening and closing, as well as different
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interactions between the receptors and ATP [8]. For example, the substitution of
glycine, located in the lower body, to alanine in the P2X4 receptor resulted in a more
rigid structure, decreased ATP sensitivity, slower activation, and desensitization [31].
2.2 Molecular docking
One of the first steps in a computational drug discovery campaign is molecular
docking. Molecular docking, or simply docking, is a computational method that
predicts the favored binding mode of one molecule to another when they may form
a complex. Usually, the binding molecule, known as a ligand, has its rotational or
translational space probed, while the other particle, known as the receptor, remains
rigid. A receptor structure can originate from modeling or experimental
approaches, such as comparative modeling and crystallographic structures. Several
docking programs and tools are available for both academic and commercial uses,
such as AutoDock [32], DOCK [33], Glide [34], and GOLD [35]. Docking programs
consist of a search algorithm and score functions that return a conformation of the
ligand, known as a pose.
In the algorithm search, the ligand conformation is evaluated recursively until
convergence to minimum energy is reached [31]. In docking methods, the energy is
estimated by a scoring function that ranks the conformations, usually by the sum of
electrostatic and van der Waals energies. A docking run does not require a lot of
computational power, taking from seconds to a few minutes at most to detect a
conformation [36]. Although docking approaches are fast, one of the crucial opera-
tional issues is obtaining accurate results due to flexibility and score function limi-
tations [36]. Therefore, a docking result should not be viewed as a drug, but just as a
priority candidate for optimization and experimental testing.
With the existence of known P2X receptor three-dimensional structures,
searching for compounds that selectively activate or block specific P2X receptor
subtypes indicates promising therapeutic targets for many diseases, such as cancer,
pain, inflammation, cardiovascular, and endocrine conditions [37]. To date,
numerous P2X ligands have been described, mostly derivatives from the endoge-
nous agonist ATP developed to increase ATP stability and reduce its degradation
rate by extracellular ectonucleotidases [38, 39]. Other structural compound classes,
such as nucleotide derivatives, irreversible antagonists, suramin-like analogs, and
pyrimidine or purine derivatives, have been reported [37]. Therefore, strategies
that predict the druggability of a compound to a target and, in turn, contribute and
accelerate optimization are frequently applied in drug discovery campaigns.
Recently, a study performed an effort in the field of structure-based modeling and
the understanding of interactions between compounds with drug-like properties
and P2X receptors. Dal Ben and colleagues used comparative model structures for
rP2X2 and hP2X2, using the zP2X4 crystal structure as a template, to perform
docking experiments concerning ATP and ATP analogs as P2X agonists in the ATP-
binding site [37]. In addition, they also assessed nucleotide and non-nucleotide
antagonists (a P2X3 antagonist, suramin derivatives, anthraquinones, azoles, and
cyanoguanidine derivatives) in different binding sites. The docking results indi-
cated agonist interactions, which may act in a comparable way to endogenous ATP
[37]. It is also clear that, alongside mutagenesis analyses, comparative modeling and
docking can provide key residues regarding P2X receptor agonist and antagonist
potency and selectivity.
This technique was also applied to test specific ligands that already have been
tested on the wet bench. Some authors demonstrated that, in a P2Y1 model based on
the X-ray crystallography-resolved rhodopsin structure, some antagonist affinities
were very similar to that obtained in experiments [40]. Other P2Y member models
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have been described based on other G protein-coupled receptors, to discover new
antagonists; see more details in Jacobson et al. [41].
2.3 Virtual screening
Molecular docking experiments of a compound series are important and
enlightening. However, in silico screening of large chemical libraries may improve
the chance of finding candidates for optimization. Therefore, virtual screening is
the computational and low-cost counterpart of time-consuming high-throughput
screening strategies [42]. Virtual screening can be structure-based, using molecular
docking as a method, or ligand-based. Compound libraries to be screened can be
formed by thousand to millions of compounds presenting similarities, or not, to
known target ligands. However, only a small percentage of compounds from the
top-ranking conformations can be examined for interaction patterns and prioritized
to be purchased or synthesized [42].
Regarding the P2Y family, a study applying virtual screening was carried out by
Costanzi et al. [43], who tested 250,000 molecules for P2Y1. At the end of the
screening, they selected only 110 hits clustered in 59 groups. The substances
presented antagonistic behavior in a low molar range; however, compound
optimization was still required [43].
With the help of structure-based virtual screening, Caseley and co-workers were
able to identify three novel hP2X7 antagonists with micromolar potency (IC50
< 6 μM) from a library of over 100,000 structurally diverse ligands [44]. VS was
performed in the hP2X7 ATP-binding pocket (enclosing 10 Å of the site), and 42 of
the highest-ranked scores were commercially available to be tested. Ligand similar-
ity was also considered and used in inhibition tests. From functional testing, one of
the three compounds showed favored inhibition of the large pore formation without
consequence to ion channel function. Studies such as this suggest that P2X receptors
are indeed an attractive pharmacological target and that computational finds can
corroborate experiments and vice versa.
2.4 Molecular dynamics
In their most basic application, structure-based methods rely on a single “snap-
shot” of the target protein. This factor may be due to the lack of experimental or
reliable modeled structures or just the reduction of docking and virtual screening
computational demands [45]. However, with the recent progress in computational
power, methods that account for structural flexibility can replicate in solution
dynamics. One of the most applied methods to investigate protein motion, with or
without a ligand, is known as classical molecular dynamics simulation. Molecular
dynamics (MD) comprises simulations based on Newton’s motion equation and can
designate the progress of the conformational state and energy landscape as a func-
tion of time in a feasible time scale [42]. Classical MD is used because it includes
temperatures and pressure effects, provides an alternative interpretation for exper-
iments, aids in obtaining molecular level information, and is computationally
cheaper than other MD approaches, such as quantum mechanics/molecular
mechanics (QM/MM) or quantum chemistry (MD/QC). One of the reasons for this
is that QMmethods use the Schrodinger equation solution to represent the electron-
nuclear relation considering static nuclei, since in classical MD atom nuclei use an
average field to describe the electrons [46–48].
Despite the advances in computational power, molecular dynamics simulations
still present a limited time scale, ranging from hundreds of nanoseconds to hun-
dreds of microseconds depending on the system, making its length not enough to
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sample most biological processes. In the case of transport through membranes or
channels, the massive, conformational changes during gating are complicated and
time-consuming, due to systems with over 200,000 atoms (receptor structure,
water molecules, lipid bilayer, and neutralizing ions) accomplishing, at most, hun-
dreds of nanoseconds [49]. However, even with limited simulation times, interest-
ing structural information can be obtained. For instance, regarding a molecular
dynamics simulation of the crystal structure of zfP2X4, it was possible to infer that
ATP binding may terminate hydrophobic interactions between the left flipper and
the dorsal fin, producing a downward movement of the left flipper and upward
motion of the dorsal fin [50]. Moreover, molecular dynamics predicted ion passage
through the lateral fenestrations, which were confirmed later in cysteine
accessibility assay experiments [12, 51].
Nevertheless, molecular dynamics assessments have only been employed in a
few studies. Alternatives to sidestep time scale and length shortcomings in the ion
channel, such as coarse-grained simulations and enhanced sampling methods
(replica-exchange molecular dynamics, metadynamics, and simulated annealing),
are performed instead of classical molecular dynamics. In coarse-grained methods,
a system is represented by a reduced number of degrees of freedom, thus eliminat-
ing some interactions and allocating fewer resources than all-atom representation,
while enhanced sampling methods can help the system cross specific high-energy
barriers that separate low-energy conformations. Recently, a coarse-grained simu-
lation of a model structure of rP2X2 within a lipid bilayer was performed [44], and
the authors observed that lipids were interposed between the transmembrane heli-
ces during the simulation, thus indicating that these molecules may be able to
stabilize the open receptor state [30]. All data about the results concerning the
techniques described above (comparative modeling, molecular docking, and
molecular dynamics) could be seen in Table 1.
2.5 Artificial intelligence applied to drug discovery
Artificial intelligence (AI) is considered the hallmark of The Fourth Industrial
Revolution [52]. AI comprises several definitions but can be defined briefly as a part
of computer science capable of performing activities ascribed to human intelli-
gence, such as solving problems, with similar and, in some instances, superior
cognitive abilities, for instance, in some cases involving image recognition and
playing games, such as Go, Chess, and Shogi [53]. It is important to point out that
the game tree complexity of Go is 10360 [54]. AI is implemented through machine
learning (ML) algorithms to be used in different fields.
Currently, ML tools have been used to rapidly identify biologically active mole-
cules from libraries containing thousands of substances in a less costly manner
compared to a bench approach [55, 56]. As mentioned previously, several ML
algorithms are available, such as k-nearest neighbors, Naïve Bayesian, decision
trees, deep neural networks, support vector machines (SVM), and random forest,
although the two most applied in this decade which aimed at drug discovery have
been SVM and deep neural networks [57]. SVM was developed by Cortes and
Vapnik, presenting applications in several fields [58]. Essentially, a hyperplane (in a
Cartesian plane, for instance, with one variable per line) separates two samples by
attempting to find the maximum distance between data points and the hyperplane.
The closest points in each side are termed support vectors. An excellent review on
SVM applied to drug discovery has been recently published by Maltarollo [59]. SVM
can predict interactions between ligand and receptors based on physicochemical
features and protein and compound descriptors, regardless of structural
information.
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Artificial neural networks are a mathematical representation of neurons, based
on how they work in the animal brain, containing several hidden layers, in some
cases. Several subtypes have been noted, but a central character is to train the
network to learn specific task patterns. In other words, the algorithm “writes” itself
through modifications, applying certain variables such as weights and bias in the
neural network. The work of a neural network is similar to the brain plasticity that
occurs in animals in order to learn new tasks, where new synaptic contacts are
formed, producing other biological networks. An interesting review of this issue has
been recently published by Carpenter [57]. Several subtypes of artificial neural
networks have been applied in drug discovery [57].
Nevertheless, the future is promising, since several drugs have been developed
applying ML. Besides, the new Google AlphaZero program has learned to play
several games by self-playing and has defeated machine learning programs such as
AlphaGo and AlphaGo Zero, which had previously defeated human Go champions
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[53, 55, 60, 61]. To date, no medicine has been produced with the aid of machine
learning algorithms, and no studies on P2 receptors are available.
3. The in silico approach: putative applications and disadvantages
Bioinformatics is a multidisciplinary field that comprises knowledge on chemis-
try, biology, and physics. This type of approach has emerged as a prevalent tool in
some areas of research, mainly those engaged in the discovery of new compounds.
The computational method user includes pharmaceutical industries that rather than
spending money and time on the selection and optimization of synthetic molecules
would be able to test several parameters of thousands of substances, at low costs
[62–64]. The development of a new compound takes from 10 to 16 years compris-
ing the initial steps of preclinical studies (also using a lot of test in animals) and,
Table 1.
P2 receptors and In Silico approaches widely applied to elucidate tridimensional strutuctures, interactions, and
binding mechanisms between P2 receptors and their suitable ligands.
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later, clinical trials, which cost about 1.2 billion, with the added factor that the
molecule can still fail during any phase of the trial. Thus, computational approaches
can be a low-cost option to test, at atomic resolution level, hypothesis that might
require costly lab experiments.
Computational approaches also have their disadvantages. In general, in silico
methodologies work with the concept of models. Models are an approximation of
reality; thus, they give only partial information of the whole biological system. For
example, structure-based methods, such as comparative modeling, molecular
docking, molecular dynamics, and other mentioned methods, often rely on three-
dimensional models from previously experimentally determined structures. How-
ever, experimentally determined structures also carries out uncertainties intro-
duced during the transformation from observed electron density data to an atomic
level structure. The position of protein atoms, ligands, water molecules, and other
cofactors might be affected by crystallization conditions, and the difficulties in
using a physiologically relevant environment might lead to ambiguous conclusions
in the structure determination. Therefore, the accuracy of structure-based methods
might be questionable due to these unreliable models.
Approximation of reality is also present in software’s algorithms. Molecular
docking, for instance, often disregards protein flexibility to speed the process, and
their ability of predicting binding affinities is limited by their small derivation/
training set used by the scoring function. Also, molecular dynamics have limited
time scale and sampling, and the physical models (force fields) used are not
intended for all types of biologically appropriate molecules failing in reproducing
properties under different temperature, pressure, pH, ion concentration, and sol-
vent types. Some approximations can be overcome by increasing computational
power and using of graphical units; however, this might go against the cost effi-
ciency promoted by means of in silico approaches, since it might be expensive to
build and maintain a cluster of computers or supercomputers.
Nevertheless, computational resources can be applied to other areas of knowl-
edge, such as in forensic analyses [65], pharmacokinetics parameter predictions
(absorption, distribution, metabolism, excretion, and toxicity) [66], binding kinet-
ics predictions (kon and Koff) [67], understanding the role of water molecules [68],
binding site predictions (orthosteric, allosteric, and hotspots) [69], compound
optimization [70], and the creation of new synthetic pathways [71].
In relation to the P2 receptors, a lot of data has been generated by computational
approaches (or molecular modeling), even describing some features not detailed by
common molecular and structural techniques as the passage of the ions through the
lateral fenestration and more recently the docking of some molecules inside the
pore of the P2X7 suggesting an allosteric pocket of binding molecules [72]. Although
there is no compound approved by FDA targeting P2 receptors derived from
molecular modeling, various compounds are under investigation in the preclinical
phase.
So, synthetic engineering is only in the beginning and will, in a very close future,
aid in facilitating an enormous number of processes in biology and other areas.
4. Conclusions
Bioinformatics is a growing subject of study that was incorporated in various
fields of knowledge as engineering, physics, chemistry, and biology. This growth
was strengthened by hardware and software improvements, mainly in the open-
source software. In biology/chemistry, the most used is the molecular modeling, a
field of science that encompasses all approaches, mimicking and modeling the
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behavior of molecules. The pharmaceutical industry has added routinely the in
silico experiments to select hits and subsequently new drugs. And in the future, it
seems that these techniques will be routinely applied in other fields, facilitating
results and saving time and cost. Moreover, the artificial intelligence development
could be directed to retouch weak point in molecular modeling approaches.
Notwithstanding, the new age began in which every process will be facilitated by
machine learning algorithms.
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